Search

In regions with high-stress roadway stress, anchor cables frequently experience damage, leading to risky pull-outs and ejections. This study aimed to determine the dynamics of such incidents, refine protective devices, and validate their efficacy in enhancing safety. Drawing from an ejection accident in the 1632 (3) roadway of Pan San Mine, a combination of laboratory experiments, theoretical analysis, simulations, and field applications was utilized. The kinetic energy and speed of cable ejections were determined from single-axis tension test data. Based on these insights, a spring-based protection device was conceptualized. Subsequent experiments and simulations evaluated the energy absorption and deformation characteristics of these devices with different diameters. The results included the following: A cable, during ejection, moved at 48 m/s. Spring protective devices of 4 mm can absorb more energy than the 5 mm, but the anti-ejection effect is poor respectively. Increasing the device diameter improved its performance, especially in controlling spring deformation rate and preventing cable lock-ups. This devised protection mechanism showed promising results when implemented in the 1511 (1) roadway of Zhangji Mine. [ABSTRACT FROM AUTHOR]

Purpose: Nanoparticle albumin-bound (nab)- paclitaxel has improved uptake by tumor cells in comparison to paclitaxel. The aim of this study was to determine the maximal tolerated dose (MTD) and the dose-limiting toxicity (DLT) of nab-paclitaxel plus cisplatin with concurrent image-guidance volume modulated arc therapy (IG-VMAT) for locally advanced cervical cancer (LACC).Patients and Methods: This single-arm phase I trial followed the standard 3 + 3 dose escalation design. Patients with histologically proven stage IB2-IVA LACC were eligible. IG-VMAT included 50.4 Gy in 28 fractions to the pelvis and 59.4 Gy simultaneous boost in 28 fractions to involved pelvic and para-aortic lymph nodes, and subsequent high dose rate intracavitary brachytherapy (HDR-IBT) at a total doses of 30.0 Gy in 5 fractions, twice a week. Concurrent chemotherapy regimen included weekly cisplatin (40 mg/m2) and weekly nab-paclitaxel at escalating doses (10, 20, 33, 50 and 70 mg/m2 per week). Duration of the planned treatment was 8 weeks. Grade 4 hematologic toxicity and grade 3 or above non-hematologic toxicity were considered as DLT. MTD was defined as the highest dose with ≤33% DLT.Results: A total of 22 patients were enrolled from September 2019 to August 2021. The most common adverse events were grade 1-3 leukopenia, diarrhea, and nausea/vomiting. A total of 4 patients (18.0%) experienced DLT: grade 3 hypokalemia at 33 mg/m2 (1 of 6 subjects), grade 3 deep vein thrombosis at 50 mg/m2 (1 of 6) and 70 mg/m2 (1 of 4), and grade 3 perineum edema at 70 mg/m2 (1 of 3). The estimated MTD was 50 mg/m2. Complete response was observed in 20 patients (90.9%).Conclusions: In patients undergoing concurrent IG-VAMT with nab-paclitaxel plus cisplatin for LACC, MTD of nab-paclitaxel was 50 mg/m2. Complete response rate was 90.9%. [ABSTRACT FROM AUTHOR]